We are not aware of any studies evaluating associations between KRAS mutational status and dyslipidemia in the NSCLC and CRC patients except that an NSCLC patient with dyslipidemia, hypertension, and the KRAS G12C mutation has been reported recently [14]. Here, KRAS is linked to non-small cell lung carcinoma.